Signaling Pathways of the Insulin-like Growth Factor Binding Proteins

• Published in: Endocrine reviews Vol. 44; no. 5; pp. 753 - 778
• Main Author: Baxter, Robert C
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.10.2023
• Subjects: Binding; Binding proteins; Cell migration; Cell signaling; Cell surface; Cell survival; DNA damage; DNA repair; Growth factors; Insulin; Insulin-like growth factors; Integrins; Intermediates; Metabolism; Nuclear receptors; Phosphorylation; Physiological aspects; Post-translation; Protein binding; Proteins; Proteolysis; Receptors; Regulatory proteins; Review; Rheumatoid arthritis; Senescence; Signal transduction; Therapeutic targets; Transforming growth factor-b; IGF binding protein; IGF; nucleus; signaling; receptor; cell-surface
• ISSN: 0163-769X; 1945-7189; 1945-7189
• DOI: 10.1210/endrev/bnad008

Abstract The 6 high-affinity insulin-like growth factor binding proteins (IGFBPs) are multifunctional proteins that modulate cell signaling through multiple pathways. Their canonical function at the cellular level is to impede access of insulin-like growth factor (IGF)-1 and IGF-2 to their principal receptor IGF1R, but IGFBPs can also inhibit, or sometimes enhance, IGF1R signaling either through their own post-translational modifications, such as phosphorylation or limited proteolysis, or by their interactions with other regulatory proteins. Beyond the regulation of IGF1R activity, IGFBPs have been shown to modulate cell survival, migration, metabolism, and other functions through mechanisms that do not appear to involve the IGF-IGF1R system. This is achieved by interacting directly or functionally with integrins, transforming growth factor β family receptors, and other cell-surface proteins as well as intracellular ligands that are intermediates in a wide range of pathways. Within the nucleus, IGFBPs can regulate the diverse range of functions of class II nuclear hormone receptors and have roles in both cell senescence and DNA damage repair by the nonhomologous end-joining pathway, thus potentially modifying the efficacy of certain cancer therapeutics. They also modulate some immune functions and may have a role in autoimmune conditions such as rheumatoid arthritis. IGFBPs have been proposed as attractive therapeutic targets, but their ubiquity in the circulation and at the cellular level raises many challenges. By understanding the diversity of regulatory pathways with which IGFBPs interact, there may still be therapeutic opportunities based on modulation of IGFBP-dependent signaling. Graphical Abstract Graphical Abstract